SELL and acute kidney injury: Consistent with immunophenotypic findings in ischemic AKI, JHU083-treated post-cisplatin AKI kidneys had CD4+ (CD44+, 50.2% ± 3.4% versus 40.9% ± 2.4%, P = 0.037; CD62L+, 37.5% ± 3.2% versus 52.5% ± 3.0%) and CD8+ T cells (CD44+, 43.3% ± 3.3% versus 26.4% ± 2.3%, P < 0.001; CD62L+, 48.9% ± 4.2% versus 76.0% ± 2.3%, P < 0.001) with primarily naive phenotypes.